# Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001)

> **NCT06621095** · PHASE2 · NOT_YET_RECRUITING · sponsor: **RenJi Hospital** · enrollment: 104 (estimated)

## Conditions studied

- Pancreatic Cancer
- First-line
- Metastatic Pancreatic Cancer

## Interventions

- **DRUG:** anlotinib + benmelstobart + nab-paclitaxel + gemcitabine
- **DRUG:** nab-paclitaxel + gemcitabine

## Key facts

- **NCT ID:** NCT06621095
- **Lead sponsor:** RenJi Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-10-30
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 104 (ESTIMATED)
- **Last updated:** 2024-10-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06621095

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06621095, "Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06621095. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*